Biomarkers are critical in the Prime Scheme as they help in the early detection, diagnosis, and monitoring of cancer. By identifying specific molecular signatures associated with different types of cancer, healthcare providers can tailor treatment plans to the individual needs of the patient. Biomarkers can also indicate how a patient is responding to treatment, allowing for real-time adjustments to therapy.
